Allogeneic anti-CD19 CAR T cells can effectively treat B-cell malignancies that progress after alloHSCT. The findings point toward a future when antigen-specific T-cell therapies will play a central role in alloHSCT.
BACKGROUND
Myeloablative allogeneic hematopoietic stem-cell transplantation is curative in children
with sickle cell disease, but in adults the procedure is unduly toxic. Graft rejection and
graft-versus-host disease (GVHD) are additional barriers to its success. We performed
nonmyeloablative stem-cell transplantation in adults with sickle cell disease.
METHODS
Ten adults (age range, 16 to 45 years) with severe sickle cell disease underwent
nonmyeloablative transplantation with CD34+ peripheral-blood stem cells, mobilized by
granulocyte colony-stimulating factor (G-CSF), which were obtained from HLA-matched siblings. The
patients received 300 cGy of total-body irradiation plus alemtuzumab before transplantation, and
sirolimus was administered afterward.
RESULTS
All 10 patients were alive at a median follow-up of 30 months after transplantation
(range, 15 to 54). Nine patients had long-term, stable donor lymphohematopoietic engraftment at
levels that sufficed to reverse the sickle cell disease phenotype. Mean (±SE)
donor–recipient chimerism for T cells (CD3+) and myeloid cells
(CD14+15+) was 53.3±8.6% and 83.3±10.3%,
respectively, in the nine patients whose grafts were successful. Hemoglobin values before
transplantation and at the last follow-up assessment were 9.0±0.3 and 12.6±0.5 g per
deciliter, respectively. Serious adverse events included the narcotic-withdrawal syndrome and
sirolimus-associated pneumonitis and arthralgia. Neither acute nor chronic GVHD developed in any
patient.
CONCLUSIONS
A protocol for nonmyeloablative allogeneic hematopoietic stem-cell transplantation that
includes total-body irradiation and treatment with alemtuzumab and sirolimus can achieve stable,
mixed donor–recipient chimerism and reverse the sickle cell phenotype.
Regulatory T cells (T reg s) that constitutively express FOXP3 are instrumental to the maintenance of tolerance and may suppress graft-versus-host disease (GVHD) in humans. To determine whether regulatory T cells in allogeneic stem cell transplants (SCTs) ameliorate GVHD after transplantation, we quantitated the coexpression of FOXP3 on CD4 ؉ T cells in 32 donor SCTs infused into HLA-matched siblings and examined GVHD incidence in respective recipients. High CD4 ؉ FOXP3 ؉ Tcell count in the donor was associated with a reduced risk of GVHD. We monitored T reg s during immune reconstitution in 21 patients with leukemia undergoing a T-cell-depleted allogeneic SCT. Early after SCT, there was a significant expansion in the CD4 ؉ FOXP3 ؉ T-cell compartment. A low CD4 ؉ FOXP3 ؉ Tcell count early after SCT (day 30) was associated with an increased risk of GVHD, and the ratio of CD4 ؉ FOXP3 ؉ T cells to CD4 ؉ CD25 ؉ FOXP3 ؊ T cells was significantly reduced in patients with GVHD, suggesting diminished control of effector T cells. Our findings suggest that graft T reg content may predict for risk of GVHD after SCT. Determining the T reg levels in the donor and manipulating T reg s early after transplantation may provide a new approach to
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.